Biotheryxincis A Clinical Stage Biopharmaceutical Company Located In San Diegocathe Company Specializes In Developing First In Class Protein Degradersprimarily Targeting Cancer And Inflammatory Diseasesutilizing Its Proprietary Prodegy Platformbiotheryx Focuses On Modulating Cereblon To Create Innovative Small Molecule Targeted Protein Degradersincluding Bifunctional Degraders And Molecular Glues The Company S Pipeline Features Several Promising Candidateswith Btx 9341 Being A Notable Oral Degrader Of Cdk4 6Which Are Significant Targets In Various Cancersespecially Hrher2Breast Cancerbtx 9341 Has Demonstrated Superior Efficacy Compared To Traditional Cdk4 6 Inhibitors In Preclinical Studiesbiotheryx Also Collaborates With Other Biopharmaceutical Companiesincluding A Partnership With Incyte To Develop Molecular Glue Degraders For Novel Oncology Targetsreflecting Its Commitment To Advancing Drug Discovery In Challenging Areas
